UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)

(Amendment No. 4)¹

Cullinan Oncology, Inc.
(Name of Issuer)
Common Stock, par value \$0.0001 per share
(Title of Class of Securities)
230031106
(CUSIP Number)
December 31, 2023
(Date of Event Which Requires Filing of this Statement)
heck the appropriate box to designate the rule pursuant to which this Schedule is filed:
□ Rule 13d-1(b)
⊠ Rule 13d-1(c)
□ Rule 13d-1(d)
The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the ubject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a rior cover page.
The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities xchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act nowever, <i>see</i> the <i>Notes</i>).

1	NAME OF REPORT	TING PERSON				
1	White of Refor					
	Biotechnology Value Fund, L.P.					
2	CHECK THE APPR	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP				
			(b) □			
3	SEC USE ONLY					
4	CITIZENSHIP OR 1	PLACE OF ORGANIZATION				
'	CITIZENSIIII OK	TENCE OF ORGANIZATION				
	Delaware					
NUMBER OF	5	SOLE VOTING POWER				
SHARES						
BENEFICIALLY		0				
OWNED BY EACH	6	SHARED VOTING POWER				
REPORTING		2,870,427 (1)				
PERSON WITH	7	SOLE DISPOSITIVE POWER				
	,					
		0				
	8	SHARED DISPOSITIVE POWER				
		2.070.427.(1)				
9	ACCDECATE AMO	2,870,427 (1) OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
9	AGGREGATE AWA	JUNI BENEFICIALET OWNED BY EACH REFORTING LERSON				
	2,870,427 (1)					
10	CHECK BOX IF TH	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES				
- 44	DED GEVIE OF GV					
11	PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)				
	6.5% (1)					
12	TYPE OF REPORT	ING PERSON				
	PN					

(1) Includes 1,196,620 Shares (as defined below) underlying certain Series A Preferred Stock (as defined below).

1	NAME OF REPORT	TING PERSON				
_						
	BVF I GP LLC					
2	CHECK THE APPR	OPRIATE BOX IF A MEMBER OF A GROUP	(a) 🗵			
		(b) □				
	GEGLIGE ONLY					
3	SEC USE ONLY					
4	CITIZENSHIP OR I	PLACE OF ORGANIZATION				
	Delaware					
NUMBER OF	5	SOLE VOTING POWER				
SHARES						
BENEFICIALLY OWNED BY	6	0 SHARED VOTING POWER				
EACH	0	SHARED VOTING FOWER				
REPORTING		2,870,427 (1)				
PERSON WITH	7	SOLE DISPOSITIVE POWER				
	_	0				
	8	SHARED DISPOSITIVE POWER				
		2,870,427 (1)				
9	AGGREGATE AMO	DUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
	2,870,427 (1)					
10	CHECK BOX IF TH	IE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES				
11	DEDCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)				
11	I ERCENT OF CLA	SS REI RESENTED DI AMOUNT IN ROW (3)				
	6.5% (1)					
12	TYPE OF REPORTI	ING PERSON				
	OO					

1	NAME OF REPORTING PERSON					
1	NAME OF KEFOK	NAME OF REFORTING FERSON				
	Biotechnology Value Fund II, L.P.					
2		OPRIATE BOX IF A MEMBER OF A GROUP	(a) 🗵			
_		OTRINE BOTT TEMBER OF TEMBER	(a) □ (b) □			
			()			
3	SEC USE ONLY					
4	CITIZENSHIP OR I	PLACE OF ORGANIZATION				
	D 1					
NUMBER OF	Delaware 5	SOLE VOTING POWER				
NUMBER OF SHARES	3	SOLE VOTING POWER				
BENEFICIALLY		0				
OWNED BY	6	SHARED VOTING POWER				
EACH						
REPORTING		1,321,582				
PERSON WITH	7	SOLE DISPOSITIVE POWER				
		0				
	8	SHARED DISPOSITIVE POWER				
		1 221 592				
9	ACCRECATE AMO	1,321,582 DUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
7	AGGREGATE AIM	JUNI BENEFICIALLI OWNED BI EACH REFORTING LERSON				
	1,321,582					
10		IE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES				
11	PERCENT OF CLA	SS REPRESENTED BY AMOUNT IN ROW (9)				
	2.10/					
12	3.1%	NC DEDCOM				
12	TYPE OF REPORT	ING PEKSUN				
	PN					
	111					

1	NAME OF REPOR	NAME OF REPORTING PERSON					
		BVF II GP LLC					
2	CHECK THE APP	ROPRIATE BOX IF A MEMBER OF A GROUP	(a) 🗵				
			(b) □				
3	SEC USE ONLY						
4	CITIZENSHIP OR	PLACE OF ORGANIZATION					
	D 1						
THE CE	Delaware	GOLE MOTING DOMED					
NUMBER OF	5	SOLE VOTING POWER					
SHARES							
BENEFICIALLY	6	0 SHARED VOTING POWER					
OWNED BY EACH	6	SHARED VOTING POWER					
REPORTING		1,321,582					
PERSON WITH	7	SOLE DISPOSITIVE POWER					
TERSON WITH	/	SOLE DISPOSITIVE FOWER					
		0					
	8	SHARED DISPOSITIVE POWER					
		1,321,582					
9	AGGREGATE AM	IOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON					
	1,321,582						
10	CHECK BOX IF T	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES					
11	PERCENT OF CL.	ASS REPRESENTED BY AMOUNT IN ROW (9)					
	3.1%						
12	TYPE OF REPORT	TING PERSON					
	00						
	OO						

	+						
1	NAME OF REPOR	NAME OF REPORTING PERSON					
		Biotechnology Value Trading Fund OS LP					
2	CHECK THE API	PROPRIATE BOX IF A MEMBER OF A GROUP	(a) 🗵				
			(b) □				
3	SEC USE ONLY						
4	CITIZENSHIP OF	R PLACE OF ORGANIZATION					
	C I-1-	1					
NUMBER OF	Cayman Isla	SOLE VOTING POWER					
SHARES	3	SOLE VOTING POWER					
BENEFICIALLY		0					
OWNED BY	6	SHARED VOTING POWER					
EACH		SIERCED VOTINGTOWER					
REPORTING		154,259					
PERSON WITH	7	SOLE DISPOSITIVE POWER					
		0					
	8	SHARED DISPOSITIVE POWER					
		154,259					
9	AGGREGATE AN	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON					
	154.050						
10	154,259	THE ACCRECATE AMOUNT BY DOWN (A) EVOLVIDED CERTARY CHARGO					
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES □						
11	DED CENT OF CI	ASS REPRESENTED BY AMOUNT IN ROW (9)					
11	I ERCENT OF CL	ASS REI RESENTED DT AMOUNT IN ROW (3)					
	Less than 1%	, 1					
12	TYPE OF REPOR						
1-							
	PN						
<u> </u>							

	1111 (E OF DEDO	ETRY O PER COV	 1			
1	NAME OF REPOR	TTING PERSON				
	DVDD - OG I-1					
	BVF Partner		_			
2	CHECK THE APP	ROPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠			
			(b) □			
3	SEC USE ONLY					
4	CITIZENSHIP OR	PLACE OF ORGANIZATION				
	Cayman Islan					
NUMBER OF	5	SOLE VOTING POWER				
SHARES						
BENEFICIALLY		0				
OWNED BY	6	SHARED VOTING POWER				
EACH		171270				
REPORTING		154,259				
PERSON WITH	7	SOLE DISPOSITIVE POWER				
		0				
	8	SHARED DISPOSITIVE POWER				
		154.250				
9	A CODEC ATE AN	154,259 OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
9	AGGKEGATE AN	IUUNI BENEFICIALLY UWNED BY EACH KEPUKIING PERSUN				
	154,259					
10		HE ACCDECATE AMOUNT IN DOW (0) EYELLIDES CEDTAIN SUADES	П			
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES					
11	PERCENT OF CI	ASS REPRESENTED BY AMOUNT IN ROW (9)				
11	LICENT OF CE.	too KEI KEOEKTED DT MINOORT IN KOW (2)				
	Less than 1%					
12	TYPE OF REPORT					
1-	l iii oi iiii ok					
	СО					
L						

1	NAME OF REPORTING PERSON					
	BVF GP Holdings LLC					
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP				
			(b) 🗆			
3	SEC USE ONLY					
4	CITIZENSHIP OR P	LACE OF ORGANIZATION				
	Delaware					
NUMBER OF SHARES	5	SOLE VOTING POWER				
BENEFICIALLY		0				
OWNED BY EACH	6	SHARED VOTING POWER				
REPORTING		4,192,009 (1)				
PERSON WITH	7	SOLE DISPOSITIVE POWER				
	_	0				
	8	SHARED DISPOSITIVE POWER				
		4,192,009 (1)				
9	AGGREGATE AMO	UNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
10	4,192,009 (1)	E A CORECATE A MOUNTE DU DOW (A) EVOLVIDES CERTA DU CHA DES				
10	CHECK BOX IF TH	E AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES				
11	DED CENT OF CLAS	OG DEDDEGENTED DV AMOUNT DI DOW (0)				
11	PERCENT OF CLAS	SS REPRESENTED BY AMOUNT IN ROW (9)				
12	9.5% (1) TYPE OF REPORTI	NIC DEDSON				
12	TIPE OF KEPORII	NU PERSON				
	00					

1	NAME OF REPORT	ING PERSON				
	BVF Partners L.P.					
2	CHECK THE APPRO	OPRIATE BOX IF A MEMBER OF A GROUP	(a) ⊠			
			(b) □			
3	SEC USE ONLY					
3	SEC OSE ONE					
4	CITIZENSHIP OR P	LACE OF ORGANIZATION				
	D.L.					
NUMBER OF	Delaware 5	SOLE VOTING POWER				
SHARES	3	SOLE VOTINGTOWER				
BENEFICIALLY		0				
OWNED BY	6	SHARED VOTING POWER				
EACH		4 202 221 (1)				
REPORTING PERSON WITH	7	4,393,321 (1) SOLE DISPOSITIVE POWER				
TERSON WITH	/	SOLE DISPOSITIVE POWER				
		0				
	8	SHARED DISPOSITIVE POWER				
		4.202.221 (1)				
9	AGGDEGATE AMO	4,393,321 (1) UNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
,	AGGREGATE AMO	ONT BENEFICIALLI OWNED BT EACH REFORTING LERSON				
	4,393,321 (1)					
10	CHECK BOX IF TH	E AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES				
11	PERCENT OF CLAS	SS REPRESENTED BY AMOUNT IN ROW (9)				
11	I LICENT OF CLAS	DE REFREDENTED DI ANIOUNI INROW (2)				
	9.99% (1)					
12	TYPE OF REPORTI	NG PERSON				
	DNI TA					
	PN, IA					

(1) Includes	1.196.620	Shares	underlying	certain	Series A	Preferred	Stock.

1	NAME OF REPORT	NAME OF REPORTING PERSON				
	BVF Inc.					
2		CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP				
	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☑ (b) □					
3	SEC USE ONLY					
3	SEC USE ONL!					
	CAMPAGE VICTOR OF P					
4	CITIZENSHIP OR P	LACE OF ORGANIZATION				
	Delaware					
NUMBER OF SHARES	5	SOLE VOTING POWER				
BENEFICIALLY		0				
OWNED BY	6	SHARED VOTING POWER				
EACH REPORTING		4,393,321 (1)				
PERSON WITH	7	SOLE DISPOSITIVE POWER				
		0				
	8	SHARED DISPOSITIVE POWER				
		4,393,321 (1)				
9	AGGREGATE AMO	OUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
	4,393,321 (1)					
10		E AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES				
11	PERCENT OF CLAS	SS REPRESENTED BY AMOUNT IN ROW (9)				
	9.99% (1)					
12	TYPE OF REPORTI	NG PERSON				
	CO					
	CO					

	·					
1	NAME OF REPO	NAME OF REPORTING PERSON				
	Mark N. Lampert					
2	CHECK THE AP	PROPRIATE BOX IF A MEMBER OF A GROUP	(a) 🗵			
			(b) □			
3	SEC USE ONLY					
4	CITIZENSHIP O	R PLACE OF ORGANIZATION				
	II. 2 . 1 Cr . 1					
NUMBER OF	United State	SOLE VOTING POWER				
NUMBER OF SHARES	3	SOLE VOTING POWER				
BENEFICIALLY		0				
OWNED BY	6	SHARED VOTING POWER				
EACH		SIMILD FORMOTOWER				
REPORTING		4,393,321 (1)				
PERSON WITH	7	SOLE DISPOSITIVE POWER				
		0				
	8	SHARED DISPOSITIVE POWER				
		4,393,321 (1)				
9	AGGREGATE A	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
	4 202 221 /					
10	4,393,321 (
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES □					
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)					
11	FERCENT OF CI	LASS REFRESENTED DI AMOUNT IN ROW (7)				
	9.99% (1)					
12	TYPE OF REPOR	RTING PERSON				
12	I THE OF REPOR	ano i baori				
	IN					

Item 1(a). Name of Issuer:

Cullinan Oncology, Inc., a Delaware corporation (the "Issuer").

Item 1(b). Address of Issuer's Principal Executive Offices:

One Main Street, Suite 1350 Cambridge, MA 02142

Item 2(a). Name of Person Filing

Item 2(b). Address of Principal Business Office or, if None, Residence

Item 2(c). Citizenship

Biotechnology Value Fund, L.P. ("BVF") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware

BVF I GP LLC ("BVF GP") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware

Biotechnology Value Fund II, L.P. ("BVF2") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware

BVF II GP LLC ("BVF2 GP") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware

Biotechnology Value Trading Fund OS LP ("Trading Fund OS") PO Box 309 Ugland House Grand Cayman, KY1-1104 Cayman Islands Citizenship: Cayman Islands

BVF Partners OS Ltd. ("Partners OS") PO Box 309 Ugland House Grand Cayman, KY1-1104 Cayman Islands Citizenship: Cayman Islands

BVF GP Holdings LLC ("BVF GPH") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware

BVF Partners L.P. ("Partners") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware

BVF Inc. 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: Delaware

Mark N. Lampert ("Mr. Lampert") 44 Montgomery St., 40th Floor San Francisco, California 94104 Citizenship: United States

Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."

Item 2(d). Title of Class of Securities:

Common Stock, par value \$0.0001 per share (the "Shares").

Item 2(e). CUSIP Number:

230031106

Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

	/x/	Not applicable.
(a)	//	Broker or dealer registered under Section 15 of the Exchange Act.
(b)	//	Bank as defined in Section 3(a)(6) of the Exchange Act.
(c)	//	Insurance company as defined in Section 3(a)(19) of the Exchange Act.
(d)	//	Investment company registered under Section 8 of the Investment Company Act.
(e)	//	An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
(f)	//	An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
(g)	//	A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
(h)	//	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
(i)	//	A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.
(j)	//	A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J).
(k)	//	Group, in accordance with Rule $13d-1(b)(1)(ii)(K)$. If filing as a non-U.S. institution in accordance with Rule $13d-1(b)(1)(ii)(J)$, please specify the type of institution:

Item 4. Ownership

(a) Amount beneficially owned:

As of the close of business on December 31, 2023, the Reporting Persons and a certain Partners managed account (the "Partners Managed Account") held an aggregate of 647,500 shares of Series A convertible preferred stock (the "Series A Preferred Stock"), convertible into an aggregate of 6,475,000 Shares. Each share of Series A Preferred Stock is convertible into 10 Shares at the option of the holder at any time, subject to certain limitations, including that the holder will be prohibited from converting its Series A Preferred Stock into Shares if, as a result of such conversion, the holder, together with its affiliates, would beneficially own a number of Shares above 9.99% of the total Common Stock then issued and outstanding immediately following the conversion of such shares of Series A Preferred Stock (the "Conversion Blocker"). As of the close of business on December 31, 2023, the Conversion Blocker limits the conversion of the Series A Preferred Stock held by the Reporting Persons and the Partners Managed Account to 1,196,620 out of the 6,475,000 Shares underlying the Series A Preferred Stock held by them.

As of the close of business on December 31, 2023, (i) BVF beneficially owned 2,870,427 Shares, including 1,196,620 Shares underlying certain Series A Preferred Stock held by it and excluding 2,303,380 Shares underlying certain Series A Preferred Stock held by it, (ii) BVF2 beneficially owned 1,321,582 Shares, excluding the 2,600,000 Shares underlying the Series A Preferred Stock held by it, and (iii) Trading Fund OS beneficially owned 154,259 Shares, excluding the 300,000 Shares underlying the Series A Preferred Stock held by it.

BVF GP, as the general partner of BVF, may be deemed to beneficially own the 2,870,427 Shares beneficially owned by BVF.

BVF2 GP, as the general partner of BVF2, may be deemed to beneficially own the 1,321,582 Shares beneficially owned by BVF2.

Partners OS, as the general partner of Trading Fund OS, may be deemed to beneficially own the 154,259 Shares beneficially owned by Trading Fund OS.

BVF GPH, as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the 4,192,009 Shares beneficially owned in the aggregate by BVF and BVF2.

Partners, as the investment manager of BVF, BVF2 and Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the 4,393,321 Shares beneficially owned in the aggregate by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Account, including 47,053 Shares held in the Partners Managed Account and excluding 75,000 Shares underlying the Series A Preferred Stock held in the Partners Managed Account.

BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 4,393,321 Shares beneficially owned by Partners.

Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 4,393,321 Shares beneficially owned by BVF Inc.

The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any Shares owned by another Reporting Person. BVF GP disclaims beneficial ownership of the Shares beneficially owned by BVF. BVF2 GP disclaims beneficial ownership of the Shares beneficially owned by Trading Fund OS. BVF GPH disclaims beneficial ownership of the Shares beneficially owned by BVF and BVF2. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the Shares beneficially owned by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Account, and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.

(b) Percent of class:

The following percentages are based upon a denominator that is the sum of (i) 42,780,644 Shares outstanding as of October 31, 2023, which is the total number of Shares outstanding as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 8, 2023, and (ii) 1,196,620 Shares underlying certain Series A Preferred Stock held by the Reporting Persons, as applicable.

As of the close of business on December 31, 2023, (i) BVF beneficially owned approximately 6.5% of the outstanding Shares, (ii) BVF2 beneficially owned approximately 3.1% of the outstanding Shares, (iii) Trading Fund OS beneficially owned less than 1% of the outstanding Shares, (iv) BVF GP may be deemed to beneficially own approximately 6.5% of the outstanding Shares, (v) BVF2 GP may be deemed to beneficially own approximately 3.1% of the outstanding Shares, (vi) Partners OS may be deemed to beneficially own less than 1% of the outstanding Shares, (vii) BVF GPH may be deemed to beneficially own approximately 9.5% of the outstanding Shares and (viii) each of Partners, BVF Inc. and Mr. Lampert may be deemed to beneficially own approximately 9.99% of the outstanding Shares (less than 1% of the outstanding Shares are held in the Partners Managed Account).

- (c) Number of shares as to which such person has:
- (i) Sole power to vote or to direct the vote

See Cover Pages Items 5-9.

(ii) Shared power to vote or to direct the vote

See Cover Pages Items 5-9.

(iii) Sole power to dispose or to direct the disposition of

See Cover Pages Items 5-9.

(iv) Shared power to dispose or to direct the disposition of

See Cover Pages Items 5-9.

Item 5. Ownership of Five Percent or Less of a Class.

Not Applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

BVF GP, BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by BVF. BVF GPH, Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by BVF2. Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the Shares beneficially owned by Trading Fund OS and held in the Partners Managed Account.

Item 7. Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable.

Item 8. Identification and Classification of Members of the Group.

See Exhibit 99.1 to the Schedule 13G filed by the Reporting Persons with the Securities and Exchange Commission on November 8, 2021.

Item 9. Notice of Dissolution of Group.

Not Applicable.

Item 10. Certifications.

By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

Dated: February 14, 2024

BIOTECHNOLOGY VALUE FUND, L.P.

By: BVF I GP LLC, its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert Chief Executive Officer

Chief Executive Officer

BVF I GP LLC

By: /s/ Mark N. Lampert

Mark N. Lampert

Chief Executive Officer

BIOTECHNOLOGY VALUE FUND II, L.P.

By: BVF II GP LLC, its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert

Chief Executive Officer

BVF II GP LLC

By: /s/ Mark N. Lampert

Mark N. Lampert

Chief Executive Officer

BVF PARTNERS OS LTD.

By: BVF Partners L.P., its sole member

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert

President

BIOTECHNOLOGY VALUE TRADING FUND OS LP

By: BVF Partners L.P., its investment manager

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert

President

BVF GP HOLDINGS LLC

By: /s/ Mark N. Lampert

Mark N. Lampert

Chief Executive Officer

BVF PARTNERS L.P.

By: BVF Inc., its general partner

By: /s/ Mark N. Lampert

Mark N. Lampert

President

BVF INC.

By: /s/ Mark N. Lampert

Mark N. Lampert

President

/s/ Mark N. Lampert

MARK N. LAMPERT

17